Midatech Pharma appoints Dr Stephen Parker as Non-Executive Chairman

Board appointment

Midatech Pharma PLC (LON:MTPH; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, has announced the appointment of Dr Stephen Parker as a Director of the Company and Non-Executive Chairman of the Board with immediate effect.

Stephen Parker has over 30 years’ experience in leadership roles both in the healthcare industry and in advisory roles. Currently, he is Chairman of Sareum Holdings plc (AIM: SAR) and Drishti Discoveries Ltd., a Non-Executive Director of MGC Pharmaceuticals Ltd (ASX,LSE: MXC) and an Executive Director of sp2 Consulting Limited.  Previously, Stephen held a number of executive and board positions at various public and private biotech companies and senior roles at leading investment banks.  Stephen has an MBA from City University and a D.Phil. in biochemistry from Oxford University.

Dr Parker is taking over from Rolf Stahel, who has resigned as a Director of the Company and stepped down as Chairman in line with his proposed retirement, previously announced on 10 June 2022.

Additional Information

The following information is disclosed pursuant to Schedule Two paragraph (g)of the AIM Rules for Companies in relation to Dr Stephen Barry Parker, aged 63:

Current Directorships and PartnershipsPrevious Directorships and Partnerships (past 5 years)
Sareum Holdings PlcSilence Therapeutics Plc
Sareum LimitedLiverpool Chirochem Limited
sp2 Consulting LimitedAlbucasis Limited
sp2 Asset Management Ltd
MGC Pharmaceuticals Limited
Drishti Discoveries Ltd.
Eternans Ltd

Dr Parker was formerly a director of Celtic Pharma Development UK Plc, Xenova Group Limited and Xenova Limited, each of which were subsidiaries of Celtic Pharma GP Limited and were placed into creditors voluntary liquidation in April 2014.

As of the date of this announcement, Dr Parker holds no ordinary shares or options in the Company. 

Save as disclosed above, there are no additional disclosures to be made in accordance with Schedule Two paragraph (g) of the AIM Rules for Companies.

Midatech Pharma PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies, to provide compelling products that have the potential to powerfully impact the lives of patients.

You might also enjoy reading  Midatech Pharma MTX110 development programme granted Orphan designation by EMA

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index